Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax-Reference-Cited by-同舟云学术

Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax

Published:2020-12-17 Issue:5 Volume:62 Page:1129-1135
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Marques-Piubelli Mario L.¹^ORCID,Schlette Ellen J.²,Khoury Joseph D.²,Furqan Fateeha³,Vega Francisco²,Soto Luisa M. Solis¹,Wistuba Ignacio I.¹,Wierda William G.⁴,Konopleva Marina⁴,Ferrajoli Alessandra⁴,Strati Paolo¹³^ORCID

Affiliation:

1. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

MD Anderson Cancer Center

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1861278

Reference38 articles.

1. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia

2. Chronic lymphocytic leukaemia

3. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status

4. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apoptosis Pathway–Associated Proteins Are Frequently Expressed in Melanoma: A Study of 32 Cases With Focus on Acral Lentiginous Melanoma;The American Journal of Dermatopathology;2024-05-07

2. Nanoporous Gold Ring‐Integrated Photothermal Intraocular Lens for Active Prevention of Posterior Capsular Opacification;Small;2022-07-07

3. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets;Blood Cancer Journal;2022-03-17

4. SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML;Clinical Lymphoma Myeloma and Leukemia;2021-12

5. BCL2 and MCL1 inhibitors for hematologic malignancies;Blood;2021-09-30